Abstracts · Scientific Abstracts

Response to a Monovalent 2009 Influenza A (H1N1) Vaccine

Greenberg, M, et al.



A novel 2009 influenza A (H1N1) virus is responsible for the first influenza pandemic in 41 years and a safe and effective vaccine is needed. A randomized, observer-blind, parallel-group trial evaluating two doses of an inactivated, split-virus 2009 H1N1 vaccine in healthy adults between the ages of 18 and 64 years is being held/conducted at a single site in Australia.


The immunogenicity and safety of the vaccine after each of two scheduled doses, administered 21 days apart were evaluated. A total of 240 subjects, equally divided into two age groups (<50 years and 50 years), were enrolled and underwent randomisation to receive either 15 µg or 30 µg of hemagglutinin antigen by intramuscular injection. The antibody titers using hemagglutination-inhibition and microneutralization assays at baseline and 21 days after vaccination were measured. The co-primary immunogenicity endpoints were the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay, the proportion of subjects with either seroconversion or a significant increase in antibody titer, and the factor increase in the geometric mean titer.


By day 21 after the first dose, antibody titers of 1:40 or more were observed in 114 of 120 subjects (95.0%) who received the 15-µg dose and in 106 of 119 subjects (89.1%) who received the 30-µg dose. A similar result was observed after the second dose of vaccine. No deaths, serious adverse reactions, or adverse events of special interest were reported. Local discomfort (e.g., injection-site tenderness or pain) was reported by 56.3% of subjects, and systemic symptoms (e.g., headache) by 53.8% of subjects after each dose. Nearly all reactions were mild to moderate in intensity.


A single 15-µg dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine-associated reactions.

Source: Resposta a uma Vacina Monovalente para a Gripe A (H1N1) 2009